Breaking News Instant updates and real-time market news.

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

, SEND

SendGrid

$30.94

0.04 (0.13%)

18:58
10/15/18
10/15
18:58
10/15/18
18:58

Fly Intel: After Hours Movers

UP AFTER EARNINGS: J.B. Hunt (JBHT) up 0.9%. ALSO HIGHER: SendGrid (SEND) up 14.1% after being acquired by Twilio (TWLO), which is down 2.5%... Hanwha Q Cells (HQCL) up 10.0% after being acquired by Hanwha Solar... Adobe (ADBE) up 5.5% after backing Q4 guidance ahead of analyst day... CryoLife (CRY) up 3.0% after preliminary Q3 revenue... Turquoise Hill (TRQ) up 0.6% after Q3 production. LOWER: JELD-WEN (JELD) down 18.4% after reporting preliminary Q3 revenue below consensus and cutting FY18 guidance... T2 Biosystems (TTOO) down 3.2% after filing $100M mixed shelf... Aclaris (ACRS) down 3.1% after buying rights to Rhofade from Allergan (AGN)... Palo Alto Networks (PANW) down 1.5% after naming new President and backing Q1 guidance... Snap (SNAP) down 0.8% after being initiated with a Hold at Loop Capital.

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

SEND

SendGrid

$30.94

0.04 (0.13%)

TWLO

Twilio

$76.26

1.27 (1.69%)

HQCL

Hanwah Q Cells

$8.20

-0.13 (-1.56%)

ADBE

Adobe

$238.05

-10.84 (-4.36%)

CRY

CryoLife

$30.64

0.42 (1.39%)

TRQ

Turquoise Hill

$1.96

-0.015 (-0.76%)

JELD

Jeld-Wen

$21.31

-0.04 (-0.19%)

TTOO

T2 Biosystems

$5.30

0.17 (3.31%)

ACRS

Aclaris Therapeutics

$13.38

-0.21 (-1.55%)

AGN

Allergan

$183.03

-0.275 (-0.15%)

PANW

Palo Alto Networks

$209.49

-2.51 (-1.18%)

SNAP

Snap

$7.41

0.225 (3.13%)

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 25

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

  • 10

    Dec

JBHT J.B. Hunt
$111.78

2.52 (2.31%)

07/16/18
LOOP
07/16/18
NO CHANGE
Target $151
LOOP
Buy
Loop says J.B. Hunt guidance has gone from 'conservative' to 'unrealistic'
After J.B. Hunt reported better than expected Q2 results but did not change its guidance, Loop Capital analyst Rick Paterson noted that his 2018 revenue forecasts now beat the company's guidance ranges in all divisions except Truck, its smallest unit. The unchanged guidance "has now gone from conservative to, arguably, unrealistic," contends Paterson, who thinks it will take time for "why didn't they raise guidance" concerns to fade. However, given his raised estimates, Paterson increased his price target on J.B. Hunt shares to $151 from $145 and keeps a Buy rating on the name.
10/05/18
CLVD
10/05/18
INITIATION
CLVD
Neutral
J.B. Hunt initiated with a Neutral at Cleveland Research
Cleveland Research analyst Chris Johnson assumed coverage on J.B. Hunt with a Neutral saying intermodal volume growth is likely limited due to rail service issues.
09/28/18
EDJN
09/28/18
DOWNGRADE
EDJN
Hold
J.B. Hunt downgraded to Hold from Buy at Edward Jones
10/10/18
LOOP
10/10/18
NO CHANGE
Target $143
LOOP
Buy
J.B. Hunt price target lowered to $143 from $151 at Loop Capital
Loop Capital analyst Rick Paterson lowered his price target for J.B. Hunt Transport Services to $143 but keeps a Buy rating on the shares. The analyst is taking a s"lightly more conservative stance on the economy, given likely deceleration in the face of the escalating trade war with China." He believes, however, that the company's contract arbitration with BASF is taking a step forward with this morning's news.
SEND SendGrid
$30.94

0.04 (0.13%)

09/04/18
KEYB
09/04/18
NO CHANGE
Target $64
KEYB
Overweight
Bandwidth price target raised to $64 from $45 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Bandwidth (BAND) to $64 from $45 as he believes 2018 marks an inflection year for cloud software APIs that are poised to go ubiquitous across the broader enterprise over the next five years. The analyst has increasing confidence in the upside levers to cloud software API business models like Amazon (AMZN), Twilio (TWLO), Bandwidth, and SendGrid (SEND). Bracelin reiterates an Overweight rating on Bandwidth shares.
09/04/18
KEYB
09/04/18
NO CHANGE
Target $42
KEYB
Overweight
SendGrid price target raised to $42 from $32 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for SendGrid (SEND) to $42 from $32 as he believes 2018 marks an inflection year for cloud software APIs that are poised to go ubiquitous across the broader enterprise over the next five years. The analyst has increasing confidence in the upside levers to cloud software API business models like Amazon (AMZN), Twilio (TWLO), Bandwidth (BAND), and SendGrid. Bracelin reiterates an Overweight rating on SendGrid shares.
04/25/18
ADAM
04/25/18
INITIATION
Target $32
ADAM
Buy
SendGrid initiated with a Buy at Canaccord
Canaccord analyst Richard Davis initiated SendGrid with a Buy saying it is a promising business as a SaaS vertical firm. He said the company has low-friction selling/adoption, a business-to-developer GTM model, and has infrastructure layers where buyers source the various components of their stack. Davis has a $32 price target on SendGrid shares.
09/24/18
FANA
09/24/18
INITIATION
Target $45
FANA
Strong Buy
SendGrid initiated with a Strong Buy at First Analysis
First Analysis analyst David Gearhart initiated SendGrid with a Strong Buy rating and a price target of $45, citing its position as a leader in email delivery and its multiple catalysts for growth. The analyst says the company should see a 20% top-line growth and improving profitability, along with free cash flow generation, over the foreseeable future amid the business trend of transition to outsourced platforms, industry volume growth, and cross-sell opportunities. Gearhart also cites SendGrid software capability to be "quickly integrated by businesses through a cloud-based API", which allows for "automated delivery of wanted transactional and marketing emails to end customer and user inboxes at scale". The analyst notes that the company's valuation of 12.6-times enterprise value to expected 2018 sales is comparable to its peer group.
TWLO Twilio
$76.26

1.27 (1.69%)

10/08/18
DBAB
10/08/18
INITIATION
DBAB
Buy
Twilio initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Michael Turrin initiated Twilio with a Buy rating and $88 price target.
10/10/18
KEYB
10/10/18
NO CHANGE
KEYB
Shopify, Salesforce should be bought on October pullback, says KeyBanc
KeyBanc analyst Brent Bracelin notes that the 55 largest SaaS stocks had an incredible run through the end of Q3, as the group benefited from robust secular tailwinds and multiple expansion with forward EV/S levels increasing by two full turns above the five-year average. That said, the "Big Chill" has quickly set in during the first nine days of October as the group is down 11% this month and 21% from the highs, on average, he adds. The analyst has identified eight high-quality SaaS stocks that he would buy on the October pullback based on attractive risk-reward and growth profiles looking out into 2020, namely Shopify (SHOP), Salesforce (CRM), Twilio (TWLO), Wix.com (WIX), Zendesk (ZEN), BlackLine (BL), Avalara (AVLR), and Mindbody (MB).
10/02/18
DADA
10/02/18
INITIATION
Target $99
DADA
Buy
Twilio initiated with a Buy at DA Davidson
DA Davidson analyst Rishi Jaluria initiated Twilio with a Buy rating and a price target of $99, citing the company's "rapid growth, market leadership position, and developer-driven model". The analyst notes he is especially positive on the company's leadership in CPaas - communications platform as a service - which is a "growing area of importance for software developers". Jaluria also points to Twilio's "developer-centric model" that focuses on product development and reliability as well as its rapid growth, with annual revenues rising 68% from 2013 to 2017.
HQCL Hanwah Q Cells
$8.20

-0.13 (-1.56%)

12/06/17
ROTH
12/06/17
NO CHANGE
ROTH
Tax bill could put 'BEAT' down on U.S. renewables, says Roth Capital
Roth Capital analyst Philip Shen believes the Senate Tax Cuts and Jobs Act includes multiple elements that could negatively affect renewable tax equity capacity, such as a cut in the corporate rate from 35% to 20%, the passage of the Base Erosion Anti-Abuse Tax, or BEAT, without exemptions for solar/wind credits, and a reduction in the number of years the product tax credit could be claimed from 10 down to four years. Near-term, the analyst believes that continued negotiations on the Hill could cause increased volatility for his universe of stocks with direct or indirect exposure to the U.S. solar and wind markets, such as AMSC (AMSC), Broadwind Energy (BWEN), 8point3 Energy (CAFD), Canadian Solar (CSIQ), Daqo New Energy (DQ), Enphase Energy (ENPH), First Solar (FSLR), Hannon Armstrong (HASI), Hanwah Q CELLS (HQCL), JA Solar (JASO), JinkoSolar (JKS), SolarEdge (SEDG), Sky Solar (SKYS), ReneSola (SOL), Sunworks (SUNW), and TPI Composites (TPIC).
04/05/18
ROTH
04/05/18
NO CHANGE
ROTH
Solar 'doges bullet' as inverters/cells/modules sidestep 301 tariffs, says Roth Capital
Roth Capital analyst Philip Shen notes that inverters, solar cells, and solar modules were not on the 301 product list released on the USTR website providing which Chinese imports will be subject to 25% tariffs. A 301 tariff that increases module or inverter costs in the U.S. could have served as another dampener of U.S. solar demand, he contends, adding that the lack of impact represents an overall positive for the industry and positive for most in his coverage universe, including Canadian Solar (CSIQ), Enphase Energy (ENPH), First Solar (FSLR), Hanwah Q CELLS (HQCL), JinkoSolar (JKS), Sunrun (RUN), SolarEdge (SEDG), ReneSola (SOL), Sunworks (SUNW), and Yingli Green Energy (YGE).
06/04/18
ROTH
06/04/18
DOWNGRADE
ROTH
Sell
Hanwah Q CELLS downgraded to Sell from Neutral at Roth Capital
06/04/18
06/04/18
DOWNGRADE
Target $5.5

Sell
Hanwah Q Cells downgraded to Sell after China policy change at Roth Capital
As previously reported, Roth Capital analyst Philip Shen downgraded Hanwah Q Cells to Sell from Neutral and lowered his price target on the stock to $5.50 from $8 after China released a "much worse than expected" new solar policy. Given the new policy, he now expects a "massive" net oversupply of potentially over 30GW.
ADBE Adobe
$238.05

-10.84 (-4.36%)

10/12/18
RBCM
10/12/18
NO CHANGE
Target $288
RBCM
Outperform
Adobe's FY19 guidance may top consensus, says RBC Capital
RBC Capital analyst Ross MacMillan kept his Outperform rating and $288 price target on Adobe ahead of its Investor Day, saying there is potential for the company to initiate FY19 guidance that would be higher than consensus, ex-Marketo deal. The analyst notes that earnings and revenue growth expectations of over 20% are possible, though he also sees the impact from adoption of ASC606 and the potential for a lower tax rate as key.
10/11/18
JPMS
10/11/18
NO CHANGE
JPMS
JPMorgan lists stand outs in Software Technology following recent selloff
The recent pullback in Software Technology stocks has not discriminated in terms of valuation, JPMorgan analyst Sterling Auty tells investors in a research note titled "Our Expected Pullback Finally Arrives." The analyst says he's seen similar selloffs in both his highest valuation stocks and even his lowest. Auty recommends "only nibbling" here and waiting for the next three to five trading sessions to see if it posts any big down days like we saw yesterday "to flush out any remaining volatility." Investors should not try to bottom pick stocks, but rather average into positions to smooth out some of the volatility, the analyst recommends. He views Adobe (ADBE), Ansys (ANSS), Aspen Technology (AZPN), DocuSign (DOCU), Guidewire (GWRE), Intuit (INTU), ServiceNow (NOW), Q2 Holdings (QTWO), Palo Alto Networks (PANW), VeriSign (VRSN) and Veeva (VEEV) as stand outs in Software Technology following the recent pullback.
10/10/18
FBCO
10/10/18
NO CHANGE
Target $300
FBCO
Outperform
User conference should reinforce Adobe's positioning, says Credit Suisse
Credit Suisse analyst Brad Zelnick anticipates Adobe's user conference and accompanying analyst day next week will reinforce Adobe's positioning as a best-of-breed digital creative, experience and marketing vendor. The analyst expects management to elaborate on Adobe's product and go-to market strategy surrounding Experience Cloud given the recent acquisitions of Magento and Marketo. Zelnick estimates Marketo is likely to be neutral to FY19 NG EPS, as he believes there will be minimal DR write-down given the invoicing mix. Adobe should also provide preliminary financial guidance for FY19 total revenue, segment revenue, EPS, and Digital Media ARR, he contends. The analyst reiterates an Outperform rating and $300 price target on the shares.
10/11/18
BMOC
10/11/18
NO CHANGE
Target $295
BMOC
Outperform
Adobe's Creative Cloud market to grow 17% per year, says BMO Capital
BMO Capital analyst Keith Bachman kept his Outperform rating and $295 price target on Adobe after his "bottom-up" analysis of the total addressable market of its Creative Cloud business. The analyst sees annualized market growth of 17% through 2021, driven by the expansion of enterprise and consumer users as well as the increase in the average revenue per user. Bachman also projects a 22% annualized revenue growth for Adobe's Creative Cloud in 2019 while anticipating a "durable" high-teen growth rate in the following two years, which he expects to further support the stock.
CRY CryoLife
$30.64

0.42 (1.39%)

03/09/18
ADAM
03/09/18
NO CHANGE
Target $28
ADAM
Buy
CryoLife price target raised to $28 from $25 at Canaccord
Canaccord analyst Jason Mills raised his price target on CryoLife to $28 from $25 on expectations that solid execution will drive upside in 2018 and provide a set up for 2019-2020. The analyst cited the company's important pipeline projects and its integration of it JOTEC acquisition. Mills reiterated his Buy rating on CryoLife shares.
08/08/18
ADAM
08/08/18
NO CHANGE
Target $36
ADAM
Buy
CryoLife price target raised to $36 from $28 at Canaccord
Canaccord analyst Jason Mills raised his price target on CryoLife to $36 from $28 following its beat and raise Q2 results. The analyst noted its solid execution and improving underlying business trends. He also noted its acquisitions are tracking ahead of plan. Mills reiterated his Buy rating on CryoLife shares.
TRQ Turquoise Hill
$1.96

-0.015 (-0.76%)

JELD Jeld-Wen
$21.31

-0.04 (-0.19%)

10/08/18
RBCM
10/08/18
NO CHANGE
Target $28
RBCM
Outperform
Jeld-Wen price target lowered to $28 from $35 at RBC Capital
RBC Capital analyst Mike Dahl lowered his price target on Jeld-Wen to $28 following the latest decision by the U.S. District Court for the Eastern District of Virginia mandating the divestiture of its Towanda facility as a "appropriate remedy" in the antitrust litigation. The analyst note that some of the recent weakness in the stock price may have reflected this expectation, but still sees the development as a negative one. Dahl also keeps his Outperform rating on Jeld-Wahl, anticipating no major financial impact from the ruling until 2020 while also pointing to the generation of significant inflow of cash from the sale which can be used on investments to improve productivity at the remaining sites.
10/08/18
BARD
10/08/18
DOWNGRADE
Target $23
BARD
Neutral
Baird sees litigation capping Jeld-Wen upside, downgrades to Neutral
Baird analyst Timothy Wojs downgraded Jeld-Wen to Neutral from Outperform and lowered his price target for the shares to $23 from $34. The stock will likely be under some pressure today following a ruling late Friday that may result in a divestiture of the company's Towanda, PA facility, Wojs tells investors in a research note. The analyst thinks the overhang from Steves litigation will cap the stock's upside over the near term, while 2019 EBITDA estimates "are still not fully washed out." As such, he believes Jeld-Wen shares will remain range bound pending better visibility.
10/09/18
NOMU
10/09/18
NO CHANGE
Target $75
NOMU
Buy
Masonite price target lowered to $75 fro $86 at Nomura Instinet
Nomura Instinet analyst Michael Wood lowered his price target for Masonite (DOOR) to $75 saying the District Court for the Eastern District of Virginia's preliminary, unfavorable ruling against Jeld-Wen (JELD) adds uncertainty. The analyst, however, keeps a Buy rating on Masonite shares.
10/08/18
10/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kimberly-Clark (KMB) downgraded to Neutral from Buy at Goldman Sachs with analyst Jason English saying his fundamental thesis, that the company's personal care organic sales momentum could sustain and pulp cost pressure was poised to abate, "proved flawed." 2. Waters (WAT) downgraded to Market Perform from Outperform at Leerink. 3. Jeld-Wen (JELD) downgraded to Neutral from Outperform at Baird with analyst Timothy Wojs saying the stock will likely be under some pressure following a ruling late Friday that may result in a divestiture of the company's Towanda, PA facility. 4. Asur (ASR) downgraded to Reduce from Hold at HSBC. 5. Glu Mobile (GLUU) downgraded to Neutral from Buy at Roth Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TTOO T2 Biosystems
$5.30

0.17 (3.31%)

09/20/18
CANT
09/20/18
INITIATION
Target $11
CANT
Overweight
T2 Biosystems initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Jordan Abrams started T2 Biosystems with an Overweight rating and $11 price target. The analyst believes the company's direct-from-whole-blood species-specific technology has the potential to change the standard of care for sepsis diagnostics.
06/01/18
LEER
06/01/18
UPGRADE
Target $12
LEER
Outperform
T2 Biosystems upgraded to Outperform with $12 target at Leerink
Leerink analyst Puneet Souda upgraded T2 Biosystems to Outperform from Market Perform and raised his price target for the shares to $12 from $5. This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B, Souda tells investors in a research note. He believes T2 is "highly underpenetrated" in its core markets, but feels it can now penetrate the broader $1.5B-$2.0B bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300M
06/01/18
LEER
06/01/18
UPGRADE
LEER
Outperform
T2 Biosystems upgraded to Outperform from Market Perform at Leerink
06/01/18
06/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying American is likely to reduce capacity starting in the post-labor day period, which should be well received by investors. 2. T2 Biosystems (TTOO) upgraded to Outperform from Market Perform at Leerink with analyst Puneet Souda saying this week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B. 3. Highwoods Properties (HIW) upgraded to Buy from Hold at Stifel with analyst John Guinee saying he believes the macro environment is changing to the positive for REITs. 4. Toyota (TM) upgraded to Outperform from Neutral at Daiwa. 5. RLJ Lodging Trust (RLJ) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she views the current valuation as attractive and sees a strong RevPAR outlook for 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ACRS Aclaris Therapeutics
$13.38

-0.21 (-1.55%)

04/10/18
CANT
04/10/18
NO CHANGE
Target $50
CANT
Overweight
Aclaris insider buying underscores attractive valuation, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen highlights "meaningful" recent insider buying from executive officers at Aclaris Therapeutics, including, CEO Neal Walker, CFO Frank Ruffo and Chairman Stephen Tullman. Chen believes the stock purchases underscore her view that Aclaris shares are undervalued. The market underappreciates the commercial opportunity for Eskata, A-101 for warts, JAK for hair loss as well as vitiligo and the Confluence assets, Chen tells investors in a research note. She keeps an Overweight rating on Aclaris Therapeutics with a $50 price target.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
03/28/18
LEER
03/28/18
INITIATION
Target $52
LEER
Outperform
Aclaris Therapeutics assumed with an Outperform at Leerink
Leerink analyst Etzer Darout assumed coverage of Aclaris Therapeutics with an Outperform rating and $52 price target. The company's lead program Eskata offers a new treatment option for patients with seborrheic keratosis with reduced risk of dyspigmentation and scarring, the analyst tells investors in a research note.
09/07/18
JEFF
09/07/18
NO CHANGE
Target $30
JEFF
Buy
Expectations for Aclaris Therapeutics' Eskata are low, says Jefferies
Jefferies analyst David Steinberg surveyed 50 physicians who treat a high volume of seborrheic keratosis patients to better understand their views on Aclaris Therapeutics' Eskata. Respondents indicated that 54% of their patients could potentially benefit from Eskata, Steinberg tells investors in a research note. Given that 83M Americans have some form of SK, the survey-derived peak sales estimate of $250M for Eskata "does not seem unreasonable," the analyst adds. He believe expectations for Eskata are low, "particularly considering the growing value" of Aclaris' late stage pipeline. Steinberg lowered his price target for the shares to $30 from $33 and keeps a Buy rating on Aclaris Therapeutics.
AGN Allergan
$183.03

-0.275 (-0.15%)

10/08/18
GUGG
10/08/18
INITIATION
Target $259
GUGG
Buy
Allergan initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Allergan with a Buy rating and $259 price target, citing his view of its sustained leadership in medical aesthetics with Botox, Juvederm, and Coolsculpting and its pipeline, including rapastinel for severe depression and abicipar for wet AMD.
09/18/18
CANT
09/18/18
NO CHANGE
Target $35
CANT
Overweight
Evolus selloff yesterday not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen sees no fundamental reason for the 12% pullback yesterday in shares of Evolus (EOLS). The stock weakness was partly attributed to the "upbeat and well-attended" investor day held by competitor Allergan (AGN) last Friday, Chen tells investors in a research note. The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well. Chen believes Allergan's investor day renewed concerns that the company is and will remain the leading botulinum toxin/aesthetics player in the space. However, this is nothing new and is already priced into Evolus' valuation, Chen contends. The analyst continues to expect the company's launch of DWP-450 in spring 2019 to exceed "modest expectations." She keeps an Overweight rating on the shares with a $35 price target.
09/17/18
RHCO
09/17/18
NO CHANGE
Target $218
RHCO
Buy
Allergan price target raised to $218 from $200 at SunTrust
SunTrust analyst John Boris raised his price target on Allergan to $218 and kept his Buy rating, saying the company's Medical Aesthetics Day presentation on Friday supports his view that its markets are "materially under-penetrated". The analyst is positive on the company's portfolio, pipeline, and commercial investment that includes a salesforce expansion of over 20% for Botox/Juvederm and CoolSculpting, which he contends should "allay competitive fears". Boris adds that he is keeping his earnings view for FY18-19, but raises his global sales forecast by FY25 by $880M to $7B.
09/27/18
MZHO
09/27/18
NO CHANGE
Target $48
MZHO
Buy
Revance selloff on Allergan data a buying opportunity, says Mizuho
Mizuho analyst Difei Yang says that while Allergan's (AGN) new data from a Phase 1b trial of higher dose Botox in moderate-to-severe glabellar lines showed better duration relative to the standard dose Botox, Revance Therapeutics (RVNC) remains best positioned to address the long-duration botulinum toxin products market. The analyst believes the weakness in Revance shares during 2018 has created buying opportunities. The analyst reiterates a Buy rating on the stock with a $48 price target.
PANW Palo Alto Networks
$209.49

-2.51 (-1.18%)

09/18/18
UBSW
09/18/18
DOWNGRADE
Target $90
UBSW
Neutral
Fortinet downgraded to Neutral on valuation at UBS
UBS analyst Fatima Boolani downgraded Fortinet to Neutral from Buy while raising her price target for the shares to $90 from $80. The company's momentum appears priced into the shares at current levels, Boolani tells investors in a research note. The analyst points out that Fortinet's valuation gap to peer Palo Alto Networks (PANW) has now fully closed. Nonetheless, Boolani think's Fortinet's near-term momentum should continue.
10/08/18
MSCO
10/08/18
NO CHANGE
MSCO
Palo Alto Networks, Fortinet price targets raised after checks at Morgan Stanley
Morgan Stanley analysts Melissa Franchi, Keith Weiss and James Faucette said their channel checks and reseller survey data support generally solid results from firewall vendors continuing into the second half of 2018 and strengthening in 2019, adding that Palo Alto Networks (PANW) remains the clear share gainer in the space. Talks also suggest the refresh activity around physical appliances remains healthy, added the analysts, who raised their price targets on Palo Alto to $276 from $262 and on Fortinet (FTNT) to $88 from $67. The firm keeps Palo Alto as its top pick in software security.
10/03/18
10/03/18
UPGRADE

Palo Alto Networks upgraded to Neutral from Best Idea Short at Arete
SNAP Snap
$7.41

0.225 (3.13%)

10/12/18
PIVT
10/12/18
UPGRADE
Target $8
PIVT
Buy
Snap upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Snap to Buy from Hold while lowering his price target for the shares to $8 from $9. The stock closed yesterday up 22c to $6.81. The analyst says that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser tells investors in a research note. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. Wieser views Snap's risk/reward as favorable following the recent selloff.
10/12/18
10/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Outperform from Neutral at Macquarie with analyst Sarah Hindlian saying she is taking advantage of the pullback in shares. 2. Netflix (NFLX) upgraded to Buy from Neutral at Citi with analyst Mark May saying the valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy. 3. Square (SQ) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying the recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company." 4. Snap (SNAP) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser saying despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." 5. Costco (COST) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
LOOP
10/15/18
INITIATION
Target $7
LOOP
Hold
Snap initiated with a Hold at Loop Capital
Loop Capital analyst Alan Gould started Snap with a Hold rating and $7 price target. The company's revenue and user growth have decelerated due to competition, a "controversial" redesign and issues with the Android version of its app, Gould tells investors in a research note. He believes that even if management can revise the app, competition from Instagram may make it difficult for Snap to reaccelerate its growth. However, the analyst adds that with an enterprise value down to $9B, Snap is now small enough to be acquired "if the controlling shareholders are willing sellers and if regulators allow such a deal."
10/12/18
10/12/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MICROSOFT UPGRADED TO OUTPERFORM AFTER PULLBACK: Macquarie analyst Sarah Hindlian upgraded Microsoft (MSFT) to Outperform from Neutral and raised her price target on the shares to $121, saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work. CITI UPGRADES NETFLIX TO BUY: Citi analyst Mark May upgraded Netflix (NFLX) to Buy from Neutral with an unchanged price target of $375. The valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy, May said. Netflix has a highly recurring subscription-based revenue business that delivers "significant value" to consumers, and its management team has a strong track record of execution, the analyst contended. Further, he believes the company's fundamentals remain strong and that is has opportunity to continue growing international subscribers. SQUARE UPGRADED TO BUY AFTER PULLBACK: Canaccord Genuity analyst Michael Graham upgraded Square (SQ) to Buy from Hold and raised his price target for the shares to $90 from $60. The recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company," Graham said. He believes the departure of CFO Sarah Friar is more about going to a promising company as CEO rather than walking away from a risk. PIVOTAL UPGRADES SNAP TO BUY: Pivotal Research analyst Brian Wieser upgraded Snap (SNAP) to Buy from Hold while lowering his price target for the shares to $8 from $9. The analyst said that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser added. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. JPMORGAN DOWNGRADES ESTEE LAUDER TO NEUTRAL: JPMorgan analyst Andrea Teixeira downgraded Estee Lauder (EL) to Neutral and lowered her price target for the shares to $138 from $154. There may be a deceleration in the travel retail channel ahead now that Chinese customs agents are implementing tighter controls at the border, according to local source, Teixeira noted. Further, she believes the de-rating in luxury peers related to the group's "outsized exposure" to Chinese consumers will likely put a cap on Estee Lauder's valuation as well. The analyst also sees less opportunity for earnings beats on margins in the near term given tariff costs.

TODAY'S FREE FLY STORIES

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:03
11/12/18
11/12
18:03
11/12/18
18:03
Hot Stocks
Pareteum to acquire iPass in all-stock transaction »

Pareteum (TEUM) and iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

NINE

Nine Energy Services

$33.58

-1.6 (-4.55%)

18:01
11/12/18
11/12
18:01
11/12/18
18:01
Earnings
Nine Energy Service reports Q3 EPS 56c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

, IPAS

iPass

$1.14

(0.00%)

18:00
11/12/18
11/12
18:00
11/12/18
18:00
Hot Stocks
Breaking Hot Stocks news story on Pareteum, iPass »

Pareteum to acquire iPass…

TEUM

Pareteum

$2.13

-0.09 (-4.05%)

IPAS

iPass

$1.14

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

BMWYY

BMW

$0.00

(0.00%)

17:57
11/12/18
11/12
17:57
11/12/18
17:57
Periodicals
BMW in talks to sell branded credit-card unit, Bloomberg says »

BMW is held talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$189.37

-16.25 (-7.90%)

17:54
11/12/18
11/12
17:54
11/12/18
17:54
Hot Stocks
Nvidia reports record adoption of new Turing T4 GPU »

Nvidia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 26

    Nov

  • 10

    Dec

GLD

SPDR Gold Trust

$113.66

-0.82 (-0.72%)

17:51
11/12/18
11/12
17:51
11/12/18
17:51
Hot Stocks
SPDR Gold Trust holdings rise to 762.00MT from 755.23MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$331.15

-19.54 (-5.57%)

17:45
11/12/18
11/12
17:45
11/12/18
17:45
Periodicals
Tesla legal executive with regulatory experience leaving, Bloomberg says »

Amid a recent fraud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 13

    Dec

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Hot Stocks
Huya reports Q3 average mobile MAUs 49.4M, up 28.2% from last year »

Q3 Average MAUs reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

VLKAY

Volkswagen

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

17:34
11/12/18
11/12
17:34
11/12/18
17:34
Periodicals
Trump close to auto tariffs in a move that may have 'massive' fallout, BI says »

According to Business…

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$115.48

-1.83 (-1.56%)

F

Ford

$9.49

0.11 (1.17%)

HMC

Honda

$28.16

-0.34 (-1.19%)

GM

General Motors

$35.71

0.01 (0.03%)

FCAU

Fiat Chrysler

$15.78

-0.48 (-2.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 14

    Nov

  • 13

    Dec

MPVD

Mountain Province Diamonds

$1.42

-0.03 (-2.07%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Mountain Province Diamonds reports Q3 EPS 8c, one estimate 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on Huya »

Huya sees Q4 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

YY

YY

$61.39

-3.34 (-5.16%)

17:32
11/12/18
11/12
17:32
11/12/18
17:32
Earnings
Breaking Earnings news story on YY »

YY sees Q4 revenue growtn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUYA

Huya

$18.50

-0.5 (-2.63%)

17:31
11/12/18
11/12
17:31
11/12/18
17:31
Earnings
Huya reports Q3 EPS 4c, consensus 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

YY

YY

$61.39

-3.34 (-5.16%)

17:31
11/12/18
11/12
17:31
11/12/18
17:31
Earnings
YY reports Q3 adjusted income per ADS $1.76, consensus $1.67 »

Reports Q3 revenue $597M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.47

-2.065 (-1.73%)

, XOM

Exxon Mobil

$79.87

-1.01 (-1.25%)

17:28
11/12/18
11/12
17:28
11/12/18
17:28
Periodicals
Breaking Periodicals news story on Chevron, Exxon Mobil »

Exxon Mobil and Chevron…

CVX

Chevron

$117.47

-2.065 (-1.73%)

XOM

Exxon Mobil

$79.87

-1.01 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 26

    Nov

ESS

Essex Property Trust

$254.54

0.59 (0.23%)

17:26
11/12/18
11/12
17:26
11/12/18
17:26
Hot Stocks
Essex Property Trust sees no significant damage to CA portfolio from fires »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:25
11/12/18
11/12
17:25
11/12/18
17:25
Hot Stocks
Roan Resources sees Q4 production 52-56 MBoe/d »

The Company is projecting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:24
11/12/18
11/12
17:24
11/12/18
17:24
Hot Stocks
Roan Resources reports Q3 total production up 30% to 46.5 MBoe/d »

Liquids production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROAN

Roan Resources

$15.90

(0.00%)

17:23
11/12/18
11/12
17:23
11/12/18
17:23
Earnings
Roan Resources reports Q3 adjusted EPS 21c, consensus 24c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.66

-1.44 (-2.99%)

17:19
11/12/18
11/12
17:19
11/12/18
17:19
Hot Stocks
Intel accelerates launch of multimode modem to support 5G rollouts »

Intel announced the Intel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 26

    Nov

KRNT

Kornit Digital

$19.15

-0.88 (-4.39%)

17:18
11/12/18
11/12
17:18
11/12/18
17:18
Earnings
Kornit Digital sees Q4 revenue $37M-$39M, consensus $38.09M »

Sees Q4 operating income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UGI

UGI Corporation

$56.47

0.45 (0.80%)

17:18
11/12/18
11/12
17:18
11/12/18
17:18
Earnings
Breaking Earnings news story on UGI Corporation »

UGI Corporation sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

APU

AmeriGas

$36.63

-0.285 (-0.77%)

17:17
11/12/18
11/12
17:17
11/12/18
17:17
Hot Stocks
Breaking Hot Stocks news story on AmeriGas »

AmeriGas sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

UGI

UGI Corporation

$56.47

0.45 (0.80%)

17:17
11/12/18
11/12
17:17
11/12/18
17:17
Earnings
UGI Corporation reports Q4 EPS 14c, consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

APU

AmeriGas

$36.63

-0.285 (-0.77%)

17:17
11/12/18
11/12
17:17
11/12/18
17:17
Earnings
AmeriGas reports Q4 EPS (46c) vs (32c) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.